VON Complete Dashboard 2024 - All Key Performance Measures

📊 Executive Summary - Centro 297 Performance

Data: VON Annual Report 2024 | N = 34 infants (VLBW ≤1500g or ≤29w6d)

Performance Level	Count	Metriche	Impact
🟢 TOP QUARTILE (Q1)	8/17	47%	✅ ECCELLENZA
🟡 ABOVE MEDIAN	4/17	24%	✅ BUONA
🟠 BELOW MEDIAN	3/17	18%	⚠️ ATTENZIONE
🔴 BOTTOM QUARTILE (Q4)	2/17	12%	🚨 CRITICA

🎯 POSIZIONAMENTO GENERALE: Top Performer VON Network (71% metriche sopra mediana)

—

📈 Primary Outcomes - Mortality Composite

Mortality & Morbidity Analysis

Metrica	Centro 297 (%)	VON Median (%)	Quartile	Gap	Performance
Mortality	2.9	13.9	🟢 Q1	-11.0	✅ ECCELLENTE
Mortality Excluding Early	2.9	9.0	🟢 Q1	-6.1	✅ ECCELLENTE
Death or Morbidity	35.3	41.2	🟡 Q1-Q2	-5.9	✅ BUONA
Any Late Infection	5.9	8.2	🟡 Q1-Q2	-2.3	✅ BUONA
Necrotizing Enterocolitis	14.7	3.4	🔴 Q4	+11.3	🚨 CRITICA

—

2. ORGAN-SPECIFIC MORBIDITIES - Control Chart ===== 📈 Neurological, Pulmonary & Ocular Outcomes ===== <achart> { "chart": { "type": "line", "height": 450, "background": "#fafafa" }, "title": { "text": "Organ-Specific Morbidities - Centro 297 Performance", "align": "center" }, "subtitle": { "text": "2024 vs VON Network Benchmarks", "align": "center" }, "series": [ { "name": "🏥 Centro 297", "data": [11.1, 11.8, 5.9, 0.0, 0.0], "color": "#DC3545" }, { "name": "🎯 VON Median", "data": [23.1, 2.9, 6.0, 0.0, 2.6], "color": "#28A745" }, { "name": "🔵 Q1 Target", "data": [11.1, 0.0, 0.0, 0.0, 0.0], "color": "#0066CC" }, { "name": "🔴 Q3 Limit", "data": [36.4, 5.8, 10.2, 3.2, 7.5], "color": "#FF6B6B" } ], "xaxis": { "categories": [ "Chronic Lung Disease", "Pneumothorax", "Severe IVH", "Cystic PVL", "Severe ROP" ], "labels": { "rotate": -45, "style": { "fontSize": "11px" } } }, "yaxis": { "title": { "text": "Percentage (%)" }, "min": 0, "max": 40 }, "markers": { "size": [8, 6, 4, 4] }, "stroke": { "width": [4, 3, 2, 2], "dashArray": [0, 0, 5, 3] }, "annotations": { "points": [ { "x": 1, "y": 11.8, "marker": { "size": 10, "fillColor": "#FF0000" }, "label": { "text": "CRITICAL", "style": { "color": "#fff", "background": "#FF0000" } } } ] } } </achart> ==== Organ-Specific Morbidity Analysis ==== ^ Metrica ^ Centro 297 (%) ^ VON Median (%) ^ Quartile ^ O-E ^ Performance ^ | **Chronic Lung Disease <33w** | 11.1 | 23.1 | 🟢 **Q1** | -1 | ✅ ECCELLENTE | | **Pneumothorax** | 11.8 | 2.9 | 🔴 **Q4** | 0 | 🚨 CRITICA | | **Severe IVH** | 5.9 | 6.0 | 🟡 Q1-Q2 | 0 | ✅ BUONA | | **Cystic PVL** | 0.0 | 0.0 | 🟢 **Q1** | 0 | ✅ ECCELLENTE | | **Severe ROP** | 0.0 | 2.6 | 🟢 **Q1** | 0 | ✅ ECCELLENTE | --- 3. DISCHARGE OUTCOMES & GROWTH - Control Chart

📈 Discharge Quality & Growth Parameters

Discharge Quality Metrics

Metrica	Centro 297 (%)	VON Median (%)	Quartile	Target	Performance
Any Human Milk	61.3	63.0	🟡 Q1-Q2	>50%	✅ BUONA
Oxygen at Discharge	0.0	4.9	🟢 Q1	0%	✅ ECCELLENTE
Monitor at Discharge	0.0	4.5	🟢 Q1	0%	✅ ECCELLENTE
Discharge Weight >3rd	71.4	72.7	🟡 Q2-Q3	>70%	✅ BUONA
Head Circumference >3rd	96.4	88.1	🟢 Q1	>80%	✅ ECCELLENTE
Discharge Weight >10th	57.1	50.0	🟡 Q1-Q2	>50%	✅ BUONA
Head Circumference >10th	85.7	69.6	🟢 Q1	>70%	✅ ECCELLENTE

—

4. LENGTH OF STAY ANALYSIS ===== 📊 Efficiency Metrics - Days to Disposition ===== <achart> { "chart": { "type": "column", "height": 400 }, "title": { "text": "Length of Stay Comparison - Centro 297 vs Network", "align": "center" }, "series": [ { "name": "Centro 297 (Days)", "data": [57, 44, 7, 55] }, { "name": "VON Median (Days)", "data": [70, 49, 13, 59] }, { "name": "Q1 Best Performance", "data": [62, 38, 7, 52] } ], "xaxis": { "categories": ["Home", "Transfer", "Died", "All Cases"], "title": { "text": "Disposition Type" } }, "yaxis": { "title": { "text": "Mean Days" } }, "colors": ["#DC3545", "#28A745", "#0066CC"], "dataLabels": { "enabled": true, "style": { "fontWeight": "bold" } } } </achart> **📊 Length of Stay Performance:** - **Home:** 57 days vs 70 median (**-13 days** - MIGLIORE) - **Transfer:** 44 days vs 49 median (**-5 days** - MIGLIORE) - **Overall:** 55 days vs 59 median (**-4 days** - EFFICIENTE) --- 5. COMPREHENSIVE SCORECARD

🎯 Complete Performance Matrix - All 17 Measures

Green Zone: Excellence (Q1 Performance)

Metrica	Centro 297	VON Q1	Status	Maintained Since
Mortality	2.9%	≤8.3%	✅ TOP 25%	2024 breakthrough
Mortality Excluding Early	2.9%	≤4.5%	✅ TOP 25%	2024 breakthrough
Chronic Lung Disease	11.1%	≤11.1%	✅ TOP 25%	2024 recovery
Cystic PVL	0.0%	≤0.0%	✅ TOP 25%	Consistently excellent
Severe ROP	0.0%	≤0.0%	✅ TOP 25%	Consistently excellent
Oxygen at Discharge	0.0%	≤0.0%	✅ TOP 25%	Consistently excellent
Monitor at Discharge	0.0%	≤0.0%	✅ TOP 25%	Consistently excellent
Head Circumference >3rd	96.4%	≥95.0%	✅ TOP 25%	Growth excellence

Yellow Zone: Above Median (Q1-Q2 Performance)

Metrica	Centro 297	VON Median	Gap	Trend
Death or Morbidity	35.3%	41.2%	-5.9	✅ Better than median
Any Late Infection	5.9%	8.2%	-2.3	✅ Better than median
Severe IVH	5.9%	6.0%	-0.1	✅ At median
Any Human Milk	61.3%	63.0%	-1.7	⚠️ Slightly below

Orange Zone: Below Median (Q2-Q3 Performance)

Metrica	Centro 297	VON Median	Gap	Action Needed
Discharge Weight >3rd	71.4%	72.7%	-1.3	🟡 Minor concern
Discharge Weight >10th	57.1%	50.0%	+7.1	✅ Actually good
Head Circumference >10th	85.7%	69.6%	+16.1	✅ Actually excellent

Red Zone: Critical Areas (Q4 Performance)

Metrica	Centro 297	VON Median	Gap	Priority
Necrotizing Enterocolitis	14.7%	3.4%	+11.3	🚨 URGENT
Pneumothorax	11.8%	2.9%	+8.9	🚨 HIGH

—

## 6. STRATEGIC DASHBOARD & ACTION PLAN

🎯 2025 Strategic Priorities

Priority 1: Critical Issues Resolution (Q1 2025)

🚨 NECROTIZING ENTEROCOLITIS - Immediate Action - Current: 14.7% vs 3.4% VON (Q4 - Bottom 25%) - Target: <7% by Q2 2025 (move to Q2-Q3) - Actions:

[ ] Emergency review feeding protocols
[ ] Audit antibiotic prophylaxis guidelines
[ ] Staff retraining on early recognition
[ ] Weekly case reviews for 6 months

⚠️ PNEUMOTHORAX - Protocol Review - Current: 11.8% vs 2.9% VON (Q4 - Bottom 25%) - Target: <6% by Q3 2025 (move to Q2-Q3) - Actions:

[ ] Ventilation strategy review
[ ] Surfactant administration protocols
[ ] Respiratory therapy training update

Priority 2: Excellence Maintenance (Ongoing)

✅ MORTALITY LEADERSHIP - Achievement: Q1 performance in both metrics - Maintain: Continue protocols that achieved breakthrough - Share: Document best practices for network

✅ CHRONIC LUNG DISEASE RECOVERY - Achievement: From Q4 (2023) to Q1 (2024) - Maintain: Current ventilation strategies - Monitor: Prevent regression to previous levels

✅ DISCHARGE QUALITY - Achievement: Q1 in 3/4 discharge metrics - Optimize: Human milk to reach >65% - Maintain: Zero oxygen/monitor discharges

Priority 3: Continuous Improvement (2025-2026)

📈 HUMAN MILK OPTIMIZATION - Current: 61.3% vs 63.0% VON - Target: >70% by end 2025 - Strategy: Leverage existing lactation protocols

📊 BENCHMARKING LEADERSHIP - Goal: Achieve Q1 performance in >80% metrics - Current: 47% Q1 performance - Timeline: 18-month improvement plan

Investment & ROI

Priority	Investment	Timeline	Expected ROI
NEC Resolution	€15,000	6 months	Move from Q4 to Q2
Pneumothorax Protocol	€8,000	9 months	Move from Q4 to Q2
Excellence Maintenance	€5,000	Ongoing	Maintain Q1 status
Human Milk Optimization	€3,000	12 months	Reach Q1 performance
TOTAL	€31,000	2025	Top 10% VON Network

Success Metrics 2025

Q2 2025 Targets: - ✅ NEC: <7% (from 14.7%) - ✅ Pneumothorax: <6% (from 11.8%) - ✅ Maintain all current Q1 metrics - ✅ Human Milk: >65%

Year-End 2025 Goal: - 🎯 >75% metrics in Q1-Q2 (vs current 71%) - 🎯 Zero Q4 metrics (vs current 2) - 🎯 VON Network Top 10% overall ranking

📊 Quick Reference Performance Card

🟢 EXCELLENT (8 metrics): Mortality, CLD, PVL, ROP, Discharge Support, Growth 🟡 GOOD (7 metrics): Morbidity, Infection, IVH, Human Milk, Weights 🔴 CRITICAL (2 metrics): NEC, Pneumothorax

Overall Grade: B+ (Excellent with 2 critical areas) Network Ranking: Estimated Top 25% 2025 Goal: A- (Top 10% with all areas resolved)